Literature DB >> 26792897

Progenitor/Stem Cell Markers in Brain Adjacent to Glioblastoma: GD3 Ganglioside and NG2 Proteoglycan Expression.

Gina Lama, Annunziato Mangiola, Gabriella Proietti, Anna Colabianchi, Cristiana Angelucci, Alessio D' Alessio, Pasquale De Bonis, Maria Concetta Geloso, Libero Lauriola, Elena Binda, Filippo Biamonte, Maria Grazia Giuffrida, Angelo Vescovi, Gigliola Sica.   

Abstract

Characterization of tissue surrounding glioblastoma (GBM) is a focus for translational research because tumor recurrence invariably occurs in this area. We investigated the expression of the progenitor/stem cell markers GD3 ganglioside and NG2 proteoglycan in GBM, peritumor tissue (brain adjacent to tumor, BAT) and cancer stem-like cells (CSCs) isolated from GBM (GCSCs) and BAT (PCSCs). GD3 and NG2 immunohistochemistry was performed in paired GBM and BAT specimens from 40 patients. Double-immunofluorescence was carried out to characterize NG2-positive cells of vessel walls. GD3 and NG2 expression was investigated in GCSCs and PCSCs whose tumorigenicity was also evaluated in Scid/bg mice. GD3 and NG2 expression was higher in tumor tissue than in BAT. NG2 decreased as the distance from tumor margin increased, regardless of the tumor cell presence, whereas GD3 correlated with neoplastic infiltration. In BAT, NG2 was coexpressed with a-smooth muscle actin (a-SMA) in pericytes and with nestin in the endothelium. Higher levels of NG2 mRNA and protein were found in GCSCs while GD3 synthase was expressed at similar levels in the 2 CSC populations. PCSCs had lower tumorigenicity than GCSCs. These data suggest the possible involvement of GD3 and NG2 in pre/pro-tumorigenic events occurring in the complex microenvironment of the tissue surrounding GBM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26792897     DOI: 10.1093/jnen/nlv012

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  14 in total

1.  Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells.

Authors:  Nicole M Collette; Cristal S Yee; Nicholas R Hum; Deepa K Murugesh; Blaine A Christiansen; LiQin Xie; Aris N Economides; Jennifer O Manilay; Alexander G Robling; Gabriela G Loots
Journal:  Bone       Date:  2016-04-19       Impact factor: 4.398

Review 2.  Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.

Authors:  Sadhana Jackson; Ayman ElAli; Daniela Virgintino; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

3.  Anatomical distribution of cancer stem cells between enhancing nodule and FLAIR hyperintensity in supratentorial glioblastoma: time to recalibrate the surgical target?

Authors:  Roberto Altieri; Giuseppe Broggi; Francesco Certo; Daniela Pacella; Giacomo Cammarata; Massimiliano Maione; Marco Garozzo; Davide Barbagallo; Michele Purrello; Rosario Caltabiano; Gaetano Magro; Giuseppe Barbagallo
Journal:  Neurosurg Rev       Date:  2022-09-28       Impact factor: 2.800

4.  Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Authors:  Serena Pellegatta; Barbara Savoldo; Natalia Di Ianni; Cristina Corbetta; Yuhui Chen; Monica Patané; Chuang Sun; Bianca Pollo; Soldano Ferrone; Francesco DiMeco; Gaetano Finocchiaro; Gianpietro Dotti
Journal:  Sci Transl Med       Date:  2018-02-28       Impact factor: 17.956

5.  Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.

Authors:  Alessio D'Alessio; Gabriella Proietti; Gina Lama; Filippo Biamonte; Libero Lauriola; Umberto Moscato; Angelo Vescovi; Annunziato Mangiola; Cristiana Angelucci; Gigliola Sica
Journal:  Oncotarget       Date:  2016-11-29

6.  Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.

Authors:  Marta Mellai; Laura Annovazzi; Ilaria Bisogno; Cristiano Corona; Paola Crociara; Barbara Iulini; Paola Cassoni; Cristina Casalone; Renzo Boldorini; Davide Schiffer
Journal:  Cells       Date:  2020-06-24       Impact factor: 6.600

7.  Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis.

Authors:  Bianca Maria Scicchitano; Silvia Sorrentino; Gabriella Proietti; Gina Lama; Gabriella Dobrowolny; Angela Catizone; Elena Binda; Luigi Maria Larocca; Gigliola Sica
Journal:  Cancer Cell Int       Date:  2018-09-10       Impact factor: 5.722

Review 8.  Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.

Authors:  Margarita Bartish; Sonia V Del Rincón; Christopher E Rudd; H Uri Saragovi
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

9.  Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression.

Authors:  Cristiana Angelucci; Alessio D'Alessio; Gina Lama; Elena Binda; Annunziato Mangiola; Angelo L Vescovi; Gabriella Proietti; Laura Masuelli; Roberto Bei; Barbara Fazi; Silvia Anna Ciafrè; Gigliola Sica
Journal:  Oncotarget       Date:  2018-06-15

Review 10.  Multifaceted Functional Role of Semaphorins in Glioblastoma.

Authors:  Cristiana Angelucci; Gina Lama; Gigliola Sica
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.